Asuragen Becomes the First Certified Service Provider for Illumina Gene Expression Profiling
News Feb 15, 2007
Illumina, Inc. and Asuragen, Inc. have announced that Asuragen has successfully completed Illumina Certified Service Provider (CSPro™) certification for gene expression profiling.
Asuragen is the first commercial service provider to offer Illumina gene expression profiling services. Illumina, a San Diego, California based company, provides next-generation tools for the large-scale analysis of genetic variation and function.
“In response to customer requests, we are pleased to offer an additional choice in Gene Expression Profiling with the Illumina platform,” said Rollie Carlson, President of Asuragen. “The work performed by Asuragen and Illumina to demonstrate proficiency in the CSPro program will assure customers quality data.”
Asuragen is now accepting whole-genome (WG) samples for gene expression profiling using Illumina’s Human-6 Expression BeadChip. The Human-6 Expression BeadChip contains more than 46,000 gene targets and allows researchers to generate WG expression profiles.
Combined with Asuragen’s sample preparation, researchers can perform gene expression profiling from low amounts of starting sample, including those traditionally used in clinical settings, such as biopsies, fine needle aspirates, etc. Data from the Illumina platform is compatible with Asuragen’s Standard Service Premium and Pathways Analysis Services.
“Our commitment to quality and innovative technologies is what inspired us to become an Illumina CSPro. The Illumina platform allows us to provide solutions to the experimental needs of our customers,” said Scott Hunicke-Smith, Vice President and General Manager of Asuragen Services.
“Recent results from the MicroArray Quality Control project confirmed that Illumina’s gene expression technology is capable of generating excellent quality and performance, and boosting the number of detected genes,” he continued.
“Illumina CSPro only includes organizations that provide customers with industry-leading data quality and service in genetic analysis,” said Karen Possemato, Illumina's Director of Corporate Marketing.
“Asuragen is the first commercial service provider in the world to expand its services to include Illumina’s gene expression technology. This is a significant accomplishment for both companies, and further demonstrates the expansion of our gene expression technology in the life science community,” said Possemato.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.